Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402539 | 0.84 | — | — | |
| SCHEMBL11393783 | 0.76 | — | — | |
| SCHEMBL10765080 | 0.76 | — | — | |
| SCHEMBL23480570 | 0.76 | TDP1 (0.51) | L3MBTL1ALDH1A1NOS2ACACBHTT | |
| SCHEMBL20797184 | 0.74 | ALDH1A1 (0.38) | HPGDSMN1; SMN2ALDH1A1NOS2ACACB | |
| SCHEMBL19100018 | 0.74 | LMNA (0.53) | HPGDSMN1; SMN2L3MBTL1ALDH1A1STS | |
| SCHEMBL6639419 | 0.74 | NAMPT (0.46) | HPGDSMN1; SMN2L3MBTL1ALDH1A1ACACB | |
| SCHEMBL369224 | 0.73 | NAMPT (0.51) | HPGDALDH1A1HTTTSHRRECQL | |
| SCHEMBL5178020 | 0.73 | NOS2 (0.38) | ALDH1A1NOS2ACACBHTT | |
| SCHEMBL1608977 | 0.73 | ROCK2 (0.47) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | HSD17B3 238/4885HPGD 380/4885SMN1; SMN2 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.